| PAF (n = 127) | PerAF (n = 231) | p-value |
---|---|---|---|
Basic characteristics | |||
 Age (years) | 80 (73–84) | 79 (73–84) | 0.94 |
 Male gender | 66 (52%) | 128 (55%) | 0.53 |
 BMI (kg/m2) | 22.6 (20.6–24.9) | 22.5 (20.5–25.2) | 0.73 |
Risk stratification | |||
 CHADS2 score | 3 (2–4) | 3 (2–4) | <  0.0001 |
 CHA2DS2-VASc score | 4 (3–5) | 5 (4–6) | <  0.0001 |
 HAS-BLED score | 3 (2–3) | 3 (2–4) | 0.0004 |
  Congestive heart failure | 32 (25%) | 92 (40%) | 0.005 |
  Hypertension | 95 (75%) | 180 (78%) | 0.52 |
  Diabetes mellitus | 27 (21%) | 80 (35%) | 0.008 |
  Prior cerebral infarction or TIA | 45 (35%) | 121 (52%) | 0.003 |
  Vascular disease | 23 (18%) | 63 (27%) | 0.05 |
 Antiplatelet use | 26 (20%) | 54 (23%) | 0.60 |
 Smoking | 14 (11%) | 32 (14%) | 0.51 |
 Dyslipidemia | 78 (61%) | 140 (61%) | 0.91 |
Blood chemistry | |||
 Cre (mg/dL) | 0.83 (0.72–0.99) | 0.85 (0.71–1.11) | 0.32 |
 CCr (mL/min) | 51.6 (38.8–65.2) | 50.3 (37.3–66.7) | 0.83 |
 PT-INR | 0.99 (0.92–1.05) | 1.04 (0.96–1.15) | <  0.0001 |
Treatment | |||
 rt-PA thrombolysis | 22 (17%) | 33 (14%) | 0.45 |
 OAC before onset |  |  | <  0.0001 |
  None | 110 (87%) | 145 (63%) |  |
  WF | 11 (9%) | 72 (31%) |  |
  DOAC | 6 (5%) | 14 (6%) |  |